Prosecution Insights
Last updated: July 17, 2026
Application No. 18/693,800

METHOD FOR PRODUCING CYCLIC OLIGOSACCHARIDE, CYCLIC OLIGOSACCHARIDE AND INCLUSION AGENT

Non-Final OA §102§112
Filed
Mar 20, 2024
Priority
Sep 22, 2021 — JP 2021-154167 +1 more
Examiner
MILLER, DALE R
Art Unit
Tech Center
Assignee
KOGANEI Corporation
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
3m
Est. Remaining
79%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
448 granted / 720 resolved
+2.2% vs TC avg
Strong +17% interview lift
Without
With
+17.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
29 currently pending
Career history
748
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
63.2%
+23.2% vs TC avg
§102
7.4%
-32.6% vs TC avg
§112
4.6%
-35.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 720 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-9 are pending in the instant application and are examined on the merits herein. Priority This application is a National Stage Application of PCT/JP2022/028680, filed on 7/26/2022. The instant application claims foreign priority to JP 2021-154167 filed on 9/22/2021. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). The certified copy has been filed in the instant application on 3/20/2024. Information Disclosure Statement The information disclosure statements (IDS) dated 7/10/2024 and 10/31/2025 comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609, except where noted. Accordingly, the IDS documents have been placed in the application file and the information therein has been considered as to the merits. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-9 are rejected for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. The use of parenthetical statements renders the claim indefinite. Specifically, the limitations contained within each instance of, “()” is indefinite because it is unclear whether the limitation(s) within the parentheses are part of the claimed invention or meant as options or examples. See MPEP § 2173.05(d). For examination purposes, the broadest claim limitation(s) will be considered without taking into account preferences or examples. The claims are further indefinite because they contain molecular weights without a corresponding unit, to allow one of ordinary skill to determine the scope of the molecular weight. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 7 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yang et al. (WO 199822795A, IDS). Yang et al. discloses inclusion complexes of cyclodextrins and guest molecules, such as nitro containing organic compounds, where Yang exemplifies the cyclodextrin as heptakis (2-O-amino)-cyclodextrin. (pp. 13-14; Examples E and F) Accordingly, the instant claims are anticipated by the prior art. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DALE R MILLER whose telephone number is (571) 272-6146. The examiner can normally be reached on M-F 7:00 AM – 3:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached on (571) 270-5341. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center and the Private Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from Patent Center or Private PAIR. Status information for unpublished applications is available through Patent Center and Private PAIR to authorized users only. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /DALE R MILLER/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Mar 20, 2024
Application Filed
Jun 11, 2026
Examiner Interview (Telephonic)
Jun 16, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679861
PHOTOISOMERIZED COMPOSITIONS OF ANTHOCYANINS AND METHODS OF MAKING AND USE THEREOF
4y 0m to grant Granted Jul 14, 2026
Patent 12673968
MODIFIED GUANINES
2y 10m to grant Granted Jul 07, 2026
Patent 12661366
OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING VIRAL INFECTIONS
3y 8m to grant Granted Jun 23, 2026
Patent 12642810
Edible Energy Composition
4y 7m to grant Granted Jun 02, 2026
Patent 12642814
TOPICAL ANTIVIRAL COMPOSITIONS COMPRISING HYALURONIC ACID AND CARRAGEENAN
3y 2m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
79%
With Interview (+17.2%)
2y 7m (~3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 720 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month